Altered genome methylation is a hallmark of human malignancies.
In this study, high-throughput analyses of concordant gene methylation and expression events were performed for 91 human prostate specimens, including prostate tumor (T), matched normal adjacent to tumor (AT), and organ donor (OD). Methylated DNA in genomic DNA was immunoprecipitated with anti-methylcytidine antibodies and detected by Affymetrix human whole genome SNP 6.0 chips. Among the methylated CpG islands, 11,481 islands were found located in the promoter and exon 1 regions of 9295 genes. Genes (7641) were methylated frequently across OD, AT, and T samples, whereas 239 genes were differentially methylated in only T and 785 genes in both AT and T but not OD. Genes with promoter methylation and concordantly suppressed expression were identified. Pathway analysis suggested that many of the methylated genes in T and AT are involved in cell growth and mitogenesis. Classification analysis of the differentially methylated genes in T or OD produced a specificity of 89.4% and a sensitivity of 85.7%. The T and AT groups, however, were only slightly separated by the prediction analysis, indicating a strong field effect. A gene methylation prediction model was shown to predict prostate cancer relapse with sensitivity of 80.0% and specificity of 85.0%. These results suggest methylation patterns useful in predicting clinical outcomes of prostate cancer.
Written by:
Luo JH, Ding Y, Chen R, Michalopoulos G, Nelson J, Tseng G, Yu YP. Are you the author?
Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Reference: Am J Pathol. 2013 Jun;182(6):2028-36.
doi: 10.1016/j.ajpath.2013.02.040
PubMed Abstract
PMID: 23583283
UroToday.com Investigative Urology Section
